Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CEO Sells $8,650,009.92 in Stock

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) CEO Sanj Patel sold 92,891 shares of Kiniksa Pharmaceuticals International stock in a transaction dated Friday, October 30th. The shares were sold at an average price of $93.12, for a total transaction of $8,650,009.92. Following the sale, the chief executive officer owned 905,933 shares in the company, valued at approximately $84,360,480.96. This trade represents a 9.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kiniksa Pharmaceuticals International Stock Down 8.1%

NASDAQ KNSA opened at $88.34 on Friday. Kiniksa Pharmaceuticals International, plc has a twelve month low of $37.02 and a twelve month high of $98.48. The stock has a market cap of $6.89 billion, a P/E ratio of 67.95 and a beta of 0.07. The company’s 50-day simple moving average is $80.18 and its 200 day simple moving average is $61.10.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings results on Tuesday, October 27th. The company reported $0.56 EPS for the quarter, topping analysts’ consensus estimates of $0.37 by $0.19. The firm had revenue of $285.97 million during the quarter, compared to analysts’ expectations of $260.66 million. Kiniksa Pharmaceuticals International had a net margin of 11.58% and a return on equity of 17.27%. Research analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.30 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on KNSA shares. Wells Fargo & Company increased their target price on Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, October 28th. Weiss Ratings lowered Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c-)” rating in a research note on Wednesday, October 28th. Zacks Research cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 30th. JPMorgan Chase & Co. upped their price target on Kiniksa Pharmaceuticals International from $107.00 to $122.00 and gave the company an “overweight” rating in a research report on Friday, October 30th. Finally, Canaccord Genuity Group increased their price objective on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a research note on Wednesday, July 29th. Seven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $100.57.

Hedge Funds Weigh In On Kiniksa Pharmaceuticals International

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KNSA. Rubric Capital Management LP grew its stake in Kiniksa Pharmaceuticals International by 12.7% during the first quarter. Rubric Capital Management LP now owns 3,750,000 shares of the company’s stock worth $180,562,000 after buying an additional 421,347 shares during the last quarter. Pictet Asset Management Holding SA increased its holdings in shares of Kiniksa Pharmaceuticals International by 41.3% during the third quarter. Pictet Asset Management Holding SA now owns 860,228 shares of the company’s stock worth $64,182,000 after buying an additional 251,578 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Kiniksa Pharmaceuticals International by 18.8% in the first quarter. Dimensional Fund Advisors LP now owns 811,922 shares of the company’s stock valued at $39,086,000 after acquiring an additional 128,417 shares during the last quarter. Spruce Street Capital LP raised its stake in shares of Kiniksa Pharmaceuticals International by 75.0% in the first quarter. Spruce Street Capital LP now owns 761,063 shares of the company’s stock valued at $36,645,000 after acquiring an additional 326,081 shares during the last quarter. Finally, Bank of America Corp DE raised its stake in shares of Kiniksa Pharmaceuticals International by 220.9% in the first quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock valued at $35,436,000 after acquiring an additional 506,576 shares during the last quarter. 53.95% of the stock is currently owned by institutional investors and hedge funds.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.